Sunday, June 14, 2026

SC-Paragon Rubber Industries Vs. Pragati Rubber Mills

Composite Suits Under Copyright and Trade Mark Laws: When Jurisdiction Cannot Be Manufactured by Joinder

An Analysis of Paragon Rubber Industries v. Pragati Rubber Mills and Ors. (2013)

Introduction

In the arena of intellectual property litigation in India, one of the most practically important yet frequently misunderstood questions concerns the territorial jurisdiction of courts. Where can a plaintiff file a suit? Can a plaintiff combine two different legal claims — one under copyright law and one under trade mark law — in a single suit filed in a court that has jurisdiction over only one of those claims? The Supreme Court of India, in its landmark judgment in Paragon Rubber Industries v. Pragati Rubber Mills and Ors., decided on 29th November 2013, answered these questions with admirable clarity and finality.

The case arose from a long-running dispute between two footwear manufacturers, one based in Kerala and the other in Punjab, over the alleged infringement of trademark and copyright. The plaintiff chose to file a combined suit in the District Court at Kottayam, Kerala, relying on the special jurisdictional provision under Section 62(2) of the Copyright Act, 1957, which allows a plaintiff to sue in the court where he or she resides or carries on business — even if the defendant has no connection to that place. The central controversy was whether this provision could also pull along a separate cause of action under trade mark law, thereby conferring jurisdiction on the Kottayam court over a claim it would not otherwise be competent to try.

The Supreme Court, in a bench comprising Justice S.S. Nijjar and Justice A.K. Sikri, dismissed both the appeals arising from cross-petitions and upheld the High Court of Kerala's finding that such a composite suit was not maintainable. The decision has significant implications for intellectual property practitioners and litigants across India, and it settles a question that had seen some degree of judicial uncertainty in earlier decisions.

Factual and Procedural Background

The plaintiff in this case, Paragon Rubber Industries, is a company engaged in the manufacturing and marketing of footwear and is located in the state of Kerala. The company had been in this business since 1975, operating under a registered trademark and also holding a registered copyright associated with that trademark and its artistic representation. The defendant, Pragati Rubber Mills and others, is similarly a footwear manufacturer and marketer, but is based in Jalandhar, Punjab. The defendant also claimed to operate under a registered trademark and copyright bearing the name PRAGATI or PARAGATI, along with a distinctive device featuring a lion.

The seeds of the dispute were sown when the plaintiff alleged that the defendant's use of a similar trademark and artistic label amounted to infringement of both its copyright and its trade mark. On 19th March 2001, the plaintiff instituted a suit, registered as O.S. No. 2 of 2001, before the District Courts at Kottayam in Kerala. The suit sought relief under two separate statutes simultaneously — the Copyright Act, 1957 (referred to in the judgment as the '1957 Act') and the Trade and Merchandise Marks Act, 1958 (referred to as the '1958 Act'). Crucially, the plaintiff's own plaint admitted that the defendant's goods were not sold in Kottayam and that the defendant did not reside or carry on business within the territorial jurisdiction of the Kottayam court. The plaintiff's sole basis for filing the suit in Kottayam was Section 62(2) of the 1957 Act, which permits the plaintiff to file a copyright suit in the court within whose jurisdiction the plaintiff resides or carries on business.

The defendant responded by filing an application under Order VII Rule 11 of the Code of Civil Procedure, 1908, being I.A. No. 322 of 2004, seeking rejection of the plaint on the ground that the Kottayam court lacked territorial jurisdiction to try the suit. The trial court dismissed this application on 22nd March 2004, directing that the issue of jurisdiction would be decided at the final stage of the suit, that is, after full trial. Dissatisfied with this deferral, the defendant took the matter to the High Court of Kerala at Ernakulam by filing a Civil Revision Petition, being CRP No. 363 of 2004. The High Court, by order dated 16th June 2004, allowed the revision and directed the trial court to determine the issue of territorial jurisdiction afresh and treat it as a preliminary issue, meaning it should be decided at the outset before the main trial proceeds.

Consequently, the trial court examined jurisdiction as a preliminary issue and passed an order on 6th October 2004 holding that it did have jurisdiction to entertain the suit, relying primarily on Section 62(2) of the 1957 Act. The defendant challenged this order once again before the High Court, filing C.R.P. No. 1417 of 2004. After a detailed consideration of the matter, the High Court, by its impugned judgment dated 15th March 2011, held that the trial court's finding was incorrect. The High Court set aside the trial court's order but, in a significant exercise of discretion, granted the plaintiff the liberty to amend the plaint so as to restrict the suit to a form that would be maintainable before the Kottayam court. Both parties were aggrieved by this outcome and filed Special Leave Petitions before the Supreme Court, which were admitted and converted into Civil Appeal No. 10745 of 2013 and Civil Appeal No. 10746 of 2013 respectively.

The Core Dispute

The legal controversy at the heart of this case revolved around one fundamental question: when a plaintiff files a single suit combining claims under the Copyright Act, 1957 and the Trade and Merchandise Marks Act, 1958, and files that suit in a court that has jurisdiction to try only the copyright claim (by virtue of Section 62(2) of the 1957 Act) but not the trade mark claim, is such a composite suit maintainable?

The plaintiff, through its counsel Mr. Siddhartha Dave, argued vigorously that the suit was perfectly maintainable. The primary contention was that Section 62(2) of the 1957 Act was a special provision designed by Parliament specifically to enable copyright holders who might be resident in one part of the country to sue for infringement in a court closer to their home, rather than being forced to travel to wherever the defendant resides or does business. The provision, it was argued, conferred an additional forum — a court option over and above the normal ones prescribed by Section 20 of the Code of Civil Procedure. The plaintiff further argued that the trade mark claim in the suit was merely incidental to the copyright claim — it was not a standalone, independent cause of action but was subordinate and ancillary to the copyright grievance. When the trade mark relief is incidental in nature, the composite suit ought to be maintainable, because the court's jurisdiction under the copyright provision would naturally extend to grant incidental relief.

The plaintiff also drew attention to the fact that the Trade Marks Act, 1999 — the successor legislation to the 1958 Act — had itself incorporated a provision similar to Section 62(2) of the Copyright Act in its Section 134(2). Under this newer provision, a trade mark suit could also be filed where the plaintiff resides. The plaintiff argued that since the 1999 Act was applicable by the time the matter was being adjudicated, the Kottayam court should be allowed to exercise jurisdiction under the 1999 Act's provisions as well, making the continuation of the proceedings in Kottayam legally tenable.

Additionally, the plaintiff submitted that there existed an apparent conflict between three Supreme Court decisions — Exphar SA v. Eupharma Laboratories Ltd. (2004) 3 SCC 688, Dhodha House v. S.K. Maingi (2006) 9 SCC 41, and Dabur India Ltd. v. K.R. Industries (2008) 10 SCC 595 — and that the matter ought to be referred to a larger bench for authoritative resolution.

The defendant's position was straightforward: the suit, as framed, was a composite suit combining two independent causes of action under two different statutes. The court at Kottayam had jurisdiction under the copyright statute alone. Jurisdiction over the trade mark claim could not be conferred on the Kottayam court simply because the two claims happened to be joined in a single plaint. The defendant further pointed out that the 1999 Trade Marks Act, which the plaintiff sought to invoke, came into force only on 15th September 2003, whereas the suit was filed on 19th March 2001. The law applicable to the suit was therefore the 1958 Act, which did not contain any provision for additional forum selection akin to Section 62(2) of the 1957 Act.

Reasoning and Analysis of the Court

The Supreme Court approached the case with the clarity of a court that had already considered substantially similar questions in previous decisions. At the very outset, the bench observed that the issues raised were no longer res integra — meaning they were not fresh, open questions but had already been decided — and that the answers were to be found in the ratio of the judgments in Dhodha House (supra) and Dabur India (supra).

The Dhodha House Decision

The Supreme Court began its analysis by referring to the Dhodha House case [Dhodha House v. S.K. Maingi, MANU/SC/2524/2005 : (2006) 9 SCC 41], where the precise question — whether a court could exercise jurisdiction over a composite suit involving both copyright and trade mark claims solely on the basis of Section 62(2) of the 1957 Act — had been directly addressed. The court in Dhodha House had formulated the question clearly: whether causes of action arising under both the 1957 Act and the 1958 Act, even if overlapping, would allow a suit to be maintained in a court that has jurisdiction only by virtue of Section 62(2) of the 1957 Act?

The answer given by the Supreme Court in Dhodha House was clear: Section 62(2) of the 1957 Act was an additional forum — a parliamentary concession to copyright holders who might not otherwise be able to sue conveniently. Parliament was well aware of this provision when it enacted the Trade and Merchandise Marks Act in 1958, and yet deliberately chose not to include a similar additional forum provision in that Act. This deliberate omission, the court held, must be treated as a conscious legislative decision. It is a well-settled principle that courts should not readily presume the existence of a jurisdiction that has not been expressly conferred by statute.

Further, Dhodha House established a critical principle regarding composite suits and the Code of Civil Procedure: merely joining two causes of action in a single suit cannot create or confer jurisdiction on a court that would otherwise lack it with respect to one of those causes of action. A court must have jurisdiction over all the causes of action joined in a suit. If it has jurisdiction over one but not the other, the composite suit as a whole is not maintainable. The recourse to an additional forum is permissible only when both causes of action arise within the jurisdiction of the court that has the competence to decide all the issues.

The Dabur India Decision

The court then turned to Dabur India Ltd. v. K.R. Industries [MANU/SC/2244/2008 : (2008) 10 SCC 595], which had revisited and elaborated upon the Dhodha House principles. In Dabur India, the Supreme Court had explained what exactly is meant by a 'composite suit' in this context. A composite suit, the court clarified, is not simply any suit where two different statutory claims are clubbed together. Rather, a true composite suit within the meaning of the copyright jurisprudence is one that is fundamentally based on a copyright infringement claim, and where the court's powers are additionally invoked with respect to some incidental relief — relief that the court is otherwise competent to grant. In such a situation, the suit does not lose its character as a copyright suit merely because incidental relief is also sought.

However — and this was the critical distinction — Dabur India also made clear that two entirely separate causes of action, each founded on different facts and different statutory rights and liabilities, cannot be clubbed together under the guise of a 'composite suit' to manufacture jurisdiction in a court that lacks competence over one of them. Order 2 Rule 3 of the Code of Civil Procedure, which deals with joinder of causes of action, cannot be used as a device to create territorial jurisdiction where none exists.

No Conflict Between Dhodha House, Dabur India, and Exphar SA

The plaintiff had argued that there was a conflict between these decisions and that the matter should be referred to a larger bench. The Supreme Court firmly rejected this contention. Both Dhodha House and Dabur India, read together, consistently hold the same principle — that jurisdiction cannot be manufactured by joining two causes of action in a single suit. The Dabur India decision was not contradicting Dhodha House but rather explaining and refining it.

As for the Exphar SA case [Exphar SA v. Eupharma Laboratories Ltd., MANU/SC/0148/2004 : (2004) 3 SCC 688], the Supreme Court noted that Dabur India had already distinguished it. Exphar SA had dealt with a narrower and different question — specifically, whether Section 62(2) of the 1957 Act was to be read restrictively in a manner that would deprive copyright holders of its benefit merely because they had been served with cease-and-desist notices. The court in Exphar SA had rightly held that Section 62(2) should be construed broadly to facilitate copyright holders, and that the provision prescribed an additional ground for jurisdiction over and above Section 20 of the Code. However, this principle of liberal construction of Section 62(2) within its own domain did not extend to using Section 62(2) as a vehicle to drag in a completely different cause of action under a different statute. Dabur India had explained this distinction with precision, and the Supreme Court in the present case agreed that there was no real conflict warranting a reference to a larger bench.

Applying the Law to the Facts

Applying these principles to the facts of the present case, the Supreme Court found the matter straightforward. The plaintiff's own plaint had candidly admitted that the defendant's goods were not available in Kottayam and that the defendant did not reside or carry on business within the territorial jurisdiction of the Kottayam court. The only basis for filing the suit in Kottayam was Section 62(2) of the 1957 Act. The plaintiff had then attempted, in the words of the court, to 'camouflage' the lack of jurisdiction under the 1958 Act by confusing, mixing up, and intermingling the two causes of action in a single plaint.

The court was unequivocal: the plaintiff was fully aware that the Kottayam court had no jurisdiction to try the trade mark claim under the 1958 Act. Joining the trade mark claim with the copyright claim could not cure this deficiency. The composite suit, as framed, was not maintainable.

On the Trade Marks Act, 1999

The court also dealt decisively with the plaintiff's argument based on Section 134 of the Trade Marks Act, 1999. The 1999 Act does contain, in Section 134(2), a provision analogous to Section 62(2) of the 1957 Act — allowing a trade mark suit to be filed where the plaintiff resides. However, the 1999 Act, though enacted on 30th December 1999, was brought into force only on 15th September 2003 by a notification published in the Gazette of India. The present suit had been filed on 19th March 2001 — before the 1999 Act came into force. Section 159(4) of the 1999 Act itself makes clear that suits initiated under the 1958 Act would continue to be governed by that Act. Therefore, the applicable law for adjudicating the trade mark aspects of the suit remained the 1958 Act, which did not grant any additional forum. The High Court had correctly concluded that Section 134 of the 1999 Act could not assist the plaintiff in this case.

The Question of Allowing Plaint Amendment

Having concluded that the composite suit was not maintainable, the Supreme Court then addressed the separate controversy raised by the defendant in the second appeal. The defendant had challenged the High Court's order granting the plaintiff liberty to amend the plaint, arguing that once the suit was found to be non-maintainable, the court should have simply rejected it outright.

The Supreme Court declined to interfere with the High Court's exercise of discretion on this point. The reasoning was pragmatic and thoughtful: the High Court was conscious of the fact that under the 1999 Act (which came into force in 2003 and introduced Section 134(2)), a composite suit would indeed be maintainable in the Kottayam court. The High Court chose to grant the plaintiff an opportunity to amend the plaint — presumably to reformulate the suit so as to confine it to the copyright claim, over which the Kottayam court undeniably had jurisdiction, and to deal with the trade mark claim separately or allow it to be pursued under the now-applicable 1999 Act framework. This was a discretionary decision aimed at avoiding multiplicity of proceedings, and the Supreme Court found no error, perversity, or illegality in its exercise. The defendant could not dispute that for a pure copyright suit, the Kottayam court had full and undeniable jurisdiction under Section 62(2) of the 1957 Act. The order permitting amendment was therefore sustained.

Final Decision of the Court

The Supreme Court dismissed both Civil Appeal No. 10745 of 2013 (filed by the plaintiff Paragon Rubber Industries) and Civil Appeal No. 10746 of 2013 (filed by the defendant Pragati Rubber Mills) with no order as to costs. The judgment of the High Court of Kerala dated 15th March 2011 in CRP No. 1417 of 2004 was upheld in its entirety. The composite suit, as originally filed, was held not maintainable before the District Court at Kottayam. However, the liberty granted by the High Court to the plaintiff to amend the plaint was also confirmed, giving the plaintiff an opportunity to restructure its claims so as to make the suit maintainable.

Point of Law Settled

The case settles several important points of law in the domain of intellectual property litigation in India. First, Section 62(2) of the Copyright Act, 1957 grants an additional forum to a copyright owner — the court where the plaintiff resides or carries on business — but this additional forum is available only for copyright claims and cannot automatically extend to trade mark claims under the Trade and Merchandise Marks Act, 1958 or any other separate statute. Second, a composite suit combining copyright and trade mark claims is not maintainable in a court that has jurisdiction over only the copyright claim. Jurisdiction over all causes of action joined in a suit must exist independently; it cannot be conjured by merely clubbing two causes of action together in a single plaint. Third, the Trade Marks Act, 1958 did not contain any additional forum provision equivalent to Section 62(2) of the 1957 Act, and this omission was a deliberate legislative choice. Courts cannot read such a provision into the 1958 Act by implication or analogy. Fourth, the Trade Marks Act, 1999, while containing Section 134(2) which provides an additional forum for trade mark suits similar to the copyright provision, would apply only to suits filed after 15th September 2003 — the date on which the 1999 Act came into force. Suits filed before that date under the 1958 Act remain governed by the 1958 Act by virtue of Section 159(4) of the 1999 Act. Fifth, a composite suit within the framework of copyright law refers to a suit principally founded on copyright infringement where incidental relief is additionally claimed — not a suit combining two entirely different causes of action under two different statutes, each with its own independent factual foundation.

 

Case Details

Title: Paragon Rubber Industries Vs. Pragati Rubber Mills and Ors. AND Pragathi Rubber Mills and Ors. v. Paragon Rubber Industries

Date of Order: 29th November 2013

Case Number: Civil Appeal No. 10745 of 2013 (Arising out of SLP (C) No. 22280 of 2011) and Civil Appeal No. 10746 of 2013 (Arising out of SLP (C) No. 33453 of 2011)

Neutral Citation: MANU/SC/1247/2013

Court: Supreme Court of India

Hon'ble Judges: Justice S.S. Nijjar and Justice A.K. Sikri

 

Disclaimer: Readers are advised not to treat this as substitute for legal advise as it may contain errors in perception, interpretation, and presentation

Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi

 

Suggested SEO Titles for Legal Journal

1. Composite Suits Under Copyright and Trade Mark Law in India: Can Section 62(2) Confer Jurisdiction Over Trade Mark Claims?

2. Paragon Rubber Industries v. Pragati Rubber Mills: Supreme Court Settles Territorial Jurisdiction in IP Composite Suits

3. Section 62(2) Copyright Act 1957 and Jurisdiction in Composite Suits: A Supreme Court Analysis

4. When Does Joinder of Causes of Action Confer Jurisdiction? Lessons from Paragon Rubber Industries Case

5. Trade Mark and Copyright Composite Suits in India: Limits of Section 62(2) of the Copyright Act

6. Territorial Jurisdiction in Intellectual Property Suits: Composite Suit Doctrine Explained

7. Dhodha House, Dabur India, and Paragon Rubber: Resolving the Composite Suit Jurisdiction Debate

 

SEO Tags

Composite suit, territorial jurisdiction, Copyright Act 1957, Section 62(2), Trade Marks Act 1999, Trade and Merchandise Marks Act 1958, Section 134, Paragon Rubber Industries, Pragati Rubber Mills, Supreme Court of India, intellectual property, copyright infringement, trademark infringement, Dhodha House case, Dabur India case, Exphar SA case, Order 2 Rule 3 CPC, res integra, additional forum, joinder of causes of action, District Court Kottayam, Kerala High Court, IP litigation India, jurisdiction in copyright suits, jurisdiction in trademark suits, IP law India, footwear trademark dispute, AdvocateAjayAmitabhSuman, IPAdjutor

 

Headnote

Held — A composite suit combining claims under the Copyright Act, 1957 and the Trade and Merchandise Marks Act, 1958 is not maintainable in a court that has territorial jurisdiction only by virtue of Section 62(2) of the Copyright Act. Jurisdiction cannot be conferred upon a court merely by joining two independent causes of action in a single suit when the court lacks jurisdiction over one of them. Parliament's deliberate omission of an additional forum provision from the 1958 Act must be respected and cannot be supplied by implication. The Trade Marks Act, 1999, though containing Section 134(2) analogous to Section 62(2) of the Copyright Act, applies only to suits filed after 15th September 2003, when the 1999 Act came into force; suits filed before that date under the 1958 Act remain governed by the 1958 Act by virtue of Section 159(4) of the 1999 Act. The High Court's discretionary order permitting the plaintiff to amend the plaint to make the suit maintainable over the copyright claim alone was upheld as a proper exercise of discretion aimed at avoiding multiplicity of proceedings. Both appeals dismissed. No conflict found between Dhodha House v. S.K. Maingi [(2006) 9 SCC 41], Dabur India Ltd. v. K.R. Industries [(2008) 10 SCC 595], and Exphar SA v. Eupharma Laboratories Ltd. [(2004) 3 SCC 688].

SC-Novartis AG Vs. Union of India

Novartis AG v. Union of India: India's Landmark Stand Against Evergreening of Pharmaceutical Patents

 

Introduction

Few judgments in the history of intellectual property law in India have attracted as much national and international attention as the Supreme Court of India's decision in Novartis AG v. Union of India and Others, reported as (2013) 6 SCC 1, decided on April 1, 2013. This case raised a question that sat at the very crossroads of patent law, public health, access to medicines, and the obligations of a developing nation under international trade agreements. At its heart, the case asked a simple but deeply consequential question: should India grant a patent to a new crystalline form of an already known anti-cancer drug merely because the new form had improved physical properties, even when those improved properties did not translate into a meaningfully better therapeutic outcome for patients?

The drug in question was Gleevec or Glivec, sold by Novartis AG, a Swiss pharmaceutical giant, and used for the treatment of a deadly blood cancer called chronic myeloid leukaemia (CML) as well as certain other tumour-related conditions. The active pharmaceutical ingredient in Gleevec was the beta-crystalline form of Imatinib Mesylate, a compound derived from a broader family of chemical substances. Novartis had been selling Gleevec in India under a price that placed it out of reach for millions of patients. Generic manufacturers, particularly Indian pharmaceutical companies, were producing significantly cheaper versions of the same drug, which allowed patients across India and other developing nations to access life-saving treatment. The patent battle was thus not merely a corporate dispute. It was a contest between the patent rights of a multinational company and the right to life of thousands of cancer patients who depended on affordable medicines.

The case not only tested the limits of India's patent law, particularly the unique provision in Section 3(d) of the Patents Act, 1970 as amended by the Patents (Amendment) Act, 2005, but also examined whether India's approach to pharmaceutical patenting was consistent with its obligations under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) under the World Trade Organization. The Supreme Court, in its unanimous judgment delivered by a Bench of Justices Aftab Alam and Ranjana P. Desai, dismissed Novartis's appeals and refused the patent. The decision sent a clear message to the world: India's patent law, particularly Section 3(d), was not a mere procedural hurdle but a substantive requirement designed to prevent the practice of "evergreening," which is the attempt by pharmaceutical companies to extend their monopoly over a drug by obtaining patents on minor modifications of a known substance without any real therapeutic improvement.

 

Factual and Procedural Background

The origin of this dispute lies in an invention by Dr. Jürg Zimmermann, a scientist who worked for Ciba Geigy (which later merged with Sandoz in 1996 to form Novartis). Dr. Zimmermann invented a family of chemical compounds known as N-phenyl-2-pyrimidine-amine derivatives, which had the property of inhibiting certain tyrosine kinases — enzymes that play a role in the growth of cancer cells. This invention was patented in Europe and in the United States, where it became known as Zimmermann Patent No. 5,521,184, granted by the United States Patent and Trade Mark Office (USPTO) on May 28, 1996. The Zimmermann Patent covered the broad family of compounds, and within that family, the compound specifically identified as Example 21 — later given the international non-proprietary name "Imatinib" — was disclosed, along with its pharmaceutically acceptable salts, including Imatinib Mesylate (the methanesulfonic acid salt of Imatinib).

Novartis subsequently developed Imatinib Mesylate into a drug substance and eventually isolated a specific crystalline form of it — the beta-crystalline form — which it called beta-IM or β-IM. A subsequent US patent, Zimmermann Patent No. 6,894,051 B1, dated May 17, 2005, was granted to Novartis specifically for the beta-crystalline form (β-IM) of Imatinib Mesylate. Novartis marketed the drug under the brand name Gleevec in the United States and Glivec in other countries including India.

In India, Novartis filed a patent application in July 1998 for the beta-crystalline form of Imatinib Mesylate — that is, for β-IM — at the Chennai Patent Office. This application, numbered 1602/MAS/1998, claimed that the beta-crystalline form of Imatinib Mesylate was a new and patentable invention distinct from anything previously disclosed, including the Zimmermann Patent. The application was filed during the period when Indian patent law did not yet allow product patents for pharmaceutical substances, as Section 5 of the Patents Act, 1970 then prohibited product patents for drugs. In 1999, the Indian Government issued an Ordinance that created a "mailbox" mechanism under Article 70.8 of TRIPS, allowing applications for pharmaceutical product patents to be stored and examined once India's obligations to grant such patents under TRIPS kicked in, which happened when the Patents (Amendment) Act, 2005 came into force on January 1, 2005. Novartis's application thus remained in the "mailbox" until the 2005 Amendment opened the door for its examination.

On January 25, 2006, the Assistant Controller of Patents and Designs, Chennai, rejected Novartis's patent application on two main grounds: first, that the compound Imatinib Mesylate was already known from the Zimmermann Patent and was therefore not novel or did not involve an inventive step; and second, that the subject compound, being merely a new form of a known substance with no significantly enhanced efficacy, was excluded from patentability by virtue of Section 3(d) of the amended Patents Act, 1970.

Aggrieved by this rejection, Novartis filed appeals before the Intellectual Property Appellate Board (IPAB), Madras. In the meantime, Novartis also filed a Writ Petition in the High Court of Madras challenging the constitutional validity of Section 3(d) of the Patents Act, arguing that this provision was inconsistent with India's obligations under the TRIPS Agreement and was also vague and arbitrary in violation of Article 14 of the Constitution of India. The High Court, on August 6, 2007, in its decision in Novartis AG v. Union of India, (2007) 4 MLJ 1153, rejected the challenge to Section 3(d)'s constitutionality and its compatibility with TRIPS, holding that Section 3(d) was not violative of any constitutional provision and that TRIPS itself gave member nations the flexibility to define the patentability standards as suited their national interests. The High Court did not, however, deal with the merits of the patent claim itself, leaving those issues for the IPAB.

The IPAB, in its order dated June 26, 2009, partly affirmed the Controller's rejection. The IPAB disagreed with the Controller on the ground of lack of novelty and held that Imatinib Mesylate was not anticipated by the prior art. However, the IPAB upheld the rejection on the ground of Section 3(d), finding that Novartis had failed to demonstrate that β-IM had any significantly enhanced therapeutic efficacy as compared to the known substance Imatinib Mesylate. Novartis and other parties, including Natco Pharma Limited and Cancer Patients Aid Association, all filed appeals before the Supreme Court of India, challenging various aspects of the IPAB's reasoning.

Before the Supreme Court, Civil Appeals Nos. 2706-716 of 2013 (by Novartis), Civil Appeal No. 2728 of 2013 (by Natco Pharma Limited), and Civil Appeals Nos. 2717-27 of 2013 (by Cancer Patients Aid Association) were all heard together. The case thus came to be decided by the Supreme Court with a Bench of Justices Aftab Alam and Ranjana P. Desai.

 

The Dispute

The central legal dispute before the Supreme Court involved the correct interpretation and application of Section 3(d) of the Patents Act, 1970 as amended in 2005, along with Sections 2(1)(j) and 2(1)(ja) defining "invention" and "inventive step" respectively. However, several other important sub-disputes arose in the course of argument.

The first and primary question was whether Imatinib Mesylate — the parent substance from which β-IM was derived — was itself a "new" product when it came into being, or whether it was already a known substance taught by the Zimmermann Patent. This was significant because if Imatinib Mesylate itself was not a "new" product, then the two-stage claim by Novartis — that they invented first Imatinib Mesylate and then β-IM — could not be sustained. Novartis argued before the Supreme Court that Imatinib Mesylate was covered by the Zimmermann Patent (i.e., within its claims) but was not specifically disclosed or taught as a preparation in that patent, and therefore the step of going from Imatinib (the free base) to Imatinib Mesylate involved an inventive step. The respondents, on the other hand, particularly Cipla Ltd. (appearing through Mr. Harish N. Salve, Senior Advocate) and the Union of India, contended that Imatinib Mesylate was fully part of the teaching of the Zimmermann Patent, which disclosed preparing "pharmaceutically acceptable salts" of the compound Imatinib, and that the mesylate salt was an obvious variant known to persons skilled in pharmaceutical chemistry.

The second important sub-dispute was whether the claim for β-IM as a distinct invention could survive the test of Section 3(d) of the 1970 Act. Section 3(d) provides that the "mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance" shall not be considered an invention. The Explanation to Section 3(d) clarifies that salts, esters, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations, and other derivatives of known substances shall be considered to be the same substance, unless they differ significantly in properties with regard to efficacy. Novartis argued that β-IM had enhanced efficacy because it had 30% more bioavailability than Imatinib in free-base form, and had better physical properties such as better flow, greater thermodynamic stability, and lower hygroscopicity. The respondents argued that bioavailability improvements and physico-chemical properties were not the same as enhanced therapeutic efficacy as required by Section 3(d), and that Novartis had not produced any research data comparing the therapeutic effect of β-IM with that of Imatinib Mesylate in treating patients.

The third significant dispute related to whether Section 3(d) was an ex majore cautela (out of abundant caution) provision that should be read as subordinate to the general invention tests in Sections 2(1)(j) and 2(1)(ja), or whether it was a substantive, independent test that applied to pharmaceutical substances over and above the tests of novelty and inventive step. Novartis contended that Section 3(d) was merely a precautionary or advisory provision and that if β-IM satisfied the standard tests of novelty and inventive step, Section 3(d) could not stand in the way of granting a patent. The respondents and the courts below had held to the contrary, and this view was ultimately affirmed by the Supreme Court.

A further dispute concerned whether Novartis's own representations in other jurisdictions — particularly before the US Patent Office where it had taken the position that Imatinib Mesylate was taught by the Zimmermann Patent — could bind it before Indian proceedings. The respondents argued that Novartis was blowing hot and cold by claiming in India that Imatinib Mesylate was a new product distinct from Zimmermann while having maintained in the United States that it was fully covered by Zimmermann, and that the principle of estoppel or issue estoppel ought to prevent Novartis from contradicting its own earlier positions.

 

Reasoning and Analysis of the Judges

The Supreme Court delivered a detailed, extensively researched judgment spanning over 100 paragraphs of substantive analysis, touching upon the history of Indian patent law, the international law obligations under TRIPS, the purpose and meaning of Section 3(d), the concept of "invention" and "inventive step" under Indian law, and the factual questions concerning the substance β-IM and its characteristics.

The Court began by examining the legislative history of patent law in India, going back to the pre-independence period and the Patents and Designs Act, 1911. The Judges traced the development of Indian patent law through the Justice Rajagopala Ayyangar Report of 1959, which had strongly recommended that India should not grant product patents in the pharmaceutical sector, and which led to the enactment of the Patents Act, 1970. The Ayyangar Report had specifically noted that allowing product patents in chemicals and pharmaceuticals would lead to monopolies that would be detrimental to public health in a developing country. The Court noted that when Section 5 of the 1970 Act, which barred product patents in drugs and food, was deleted as part of India's TRIPS compliance through the Patents (Amendment) Act, 2005, it was not done in isolation. The deletion of Section 5 was accompanied by the insertion of Section 2(1)(j) and Section 2(1)(ja) — which redefined "invention" and "inventive step" — as well as the amendment to Section 3(d) and the addition of its Explanation, which set up a higher threshold for patentability specifically aimed at pharmaceutical and chemical substances.

The Court quoted from and heavily relied upon Monsanto Co. v. Coramandal Indag Products (P) Ltd., (1986) 1 SCC 642, where the Supreme Court had explained the basic quid pro quo of patent law: an inventor is given a limited monopoly in exchange for publicly disclosing the invention so that at the end of the patent term, the invention falls into the public domain and the public benefits from it. The Court emphasized that the coverage of a patent (what it claims) cannot be wider than its disclosure (what it teaches), and that Patent Law in India should not develop in a direction where the scope of a patent is determined not by the intrinsic worth of the invention but by the clever drafting of claims by skilled lawyers.

On the first major factual question — whether Imatinib Mesylate was a known substance — the Court examined the Zimmermann Patent No. 5,521,184 in considerable detail and concluded that Imatinib Mesylate was indeed a known substance disclosed within that patent. The patent not only taught the use of "pharmaceutically acceptable salts" of Imatinib but also stated the anti-tumoral properties of the compound and its methanesulfonate salt. The Court also noted two published scientific articles from reputed journals — one titled "Inhibition of the Abl Protein-Tyrosine Kinase In Vitro and In Vivo by a 2-Phenylaminopyrimidine Derivative," published in the Cancer Research Journal (Issue January–February 1996) by Dr. Zimmermann himself, and another titled "Effects of a Selective Inhibitor of the Abl Tyrosine Kinase on the Growth of Bcr-Abl Positive Cells" published in Nature Medicine (1996) — both of which specifically discussed the anti-tumoral properties of Imatinib and its mesylate salt. The Court observed that in the face of these materials, it was difficult to see how Imatinib Mesylate could be regarded as a new product.

On the question of whether Novartis was bound by its earlier representations, the Court examined the fact that when Novartis obtained US Patent No. 6,894,051 B1 for β-IM, the US Board of Patent Appeals had proceeded on the basis that Zimmermann Patent No. 5,521,184 had the teaching for making of Imatinib Mesylate from Imatinib. The Court held that Novartis, having benefited from this finding and used it in its own case in the United States, was bound by it and could not take a contrary position before Indian courts. Therefore, the development of Imatinib Mesylate from Imatinib did not qualify as an "invention" under Sections 2(1)(j) and 2(1)(ja) of the Patents Act, 1970.

Turning to the second major question — whether β-IM satisfied the test of Section 3(d) — the Court undertook a careful analysis of the meaning of the word "efficacy" as used in that provision. Novartis had argued that "efficacy" should be read broadly to include physico-chemical properties like better flow, thermodynamic stability, lower hygroscopicity, and increased bioavailability, all of which, it was said, made β-IM a better product. The Court rejected this argument with a clear and firm ruling. It held that the word "efficacy" in the context of Section 3(d), when applied to a medicine, must mean "therapeutic efficacy" — that is, the ability of the medicine to produce the desired therapeutic result in treating the disease for which it is prescribed. The Judges relied upon the New Oxford Dictionary of English (1998 edition), the IUPAC Glossary of Terms Used in Medicinal Chemistry (1998), and Goodman and Gilman's pharmacological treatise to establish that in the context of medicines, "efficacy" means therapeutic effectiveness. The Court further examined the Explanation to Section 3(d), which lists salts, polymorphs, and other derivatives as being regarded as the same substance "unless they differ significantly in properties with regard to efficacy," and held that this also pointed to therapeutic efficacy rather than general physicochemical properties.

The Court further reasoned that the legislature had consciously worded the Explanation to specify that properties "inherent" to a form — such as hygroscopicity to a polymorph or solubility to a salt — should not be taken as enhancements in efficacy unless they translate directly into therapeutic gains. Improved bioavailability, by itself, does not necessarily result in better therapeutic outcomes. Novartis had not presented any clinical data, research study, or empirical evidence showing that β-IM was more effective than Imatinib Mesylate in treating CML or any other condition. On the contrary, the drug Gleevec as marketed in India (as well as in the United States) was labelled on its packaging as containing "Imatinib Mesylate Tablets 100 mg" with each film-coated tablet containing "100 mg Imatinib (as Mesylate)." There was no reference at all to β-IM on the packaging. The Court drew the logical inference that if what was actually sold and effective was Imatinib Mesylate — not the β-IM crystalline form specifically — then the patent claim for β-IM was essentially an attempt to monopolise what was, in effect, Imatinib Mesylate, which would otherwise not be patentable. This, the Court noted, was a classic example of what the pharmaceutical industry calls "evergreening."

The Court's analysis on the TRIPS compatibility of Section 3(d) was also significant, though it was largely affirming the High Court's earlier ruling. The Judges held that TRIPS does not define what must constitute an "invention" for patentability; Article 27 of TRIPS requires member states to grant patents for inventions that are new, involve an inventive step, and are capable of industrial application, but it leaves countries free to define the standards for these requirements in their own law. Section 3(d) is India's way of defining that a mere new form of a known pharmaceutical substance, without enhanced therapeutic efficacy, does not qualify as an "invention" for Indian patent law purposes. The Court thus held that Section 3(d) does not violate TRIPS.

The Court also expressed serious concern about the broader implications for patent law development in India. In one of the most quoted paragraphs of the judgment (Paragraph 134), the Court stated that patent law in India should not develop in a manner where the scope of a patent is determined not on the intrinsic worth of the invention but by the artful drafting of claims by skilful lawyers, and where patents are traded as a commodity not for the production and marketing of the patented products but to search for someone who may be sued for infringement of the patent. This was a clear judicial articulation of the philosophy underpinning India's approach to pharmaceutical patents, and it set a strong policy marker for future cases.

The Court further discussed and considered the dichotomy between patent "coverage" and patent "disclosure," relying on several academic treatises including Terrell on the Law of Patents (16th Edition), Chisum on Patents, and academic papers from the Saint Louis University Law Journal. It held that the fundamental rule underlying the grant of patents — that the monopoly granted to the inventor is limited to what he has actually disclosed — means that a patent's coverage cannot exceed its disclosure. This has direct implications for Novartis's claim, since what was disclosed in the Zimmermann Patent (including Imatinib Mesylate) could not be the basis for a new patent merely because a specific crystalline form was now being singled out.

Several judicial decisions from foreign jurisdictions were considered during the course of arguments before the Court, including Plant Genetic Systems, N.V. v. DeKalb Genetics Corpn., 315 F 3d 1335 (Fed Cir 2003); Chiron Corpn. v. Genentech Inc., 363 F 3d 1247 (Fed Cir 2004); A.C. Edwards Ltd. v. Acme Signs & Displays Ltd., 1992 RPC 131; Astellas Pharma Inc. v. Comptroller General of Patents, 2009 EWHC 1916 (Pat); Hogan, In re, 559 F 2d 595 (CCPA 1977); and Glaverbel S.A. v. British Coal Corpn. (No. 2), 1993 RPC 90. These were considered primarily in the context of the relationship between patent coverage and disclosure, though the Court did not mechanically follow foreign precedents in arriving at its conclusion under Indian law.

 

Final Decision of the Court

The Supreme Court, by its unanimous judgment dated April 1, 2013, dismissed the Civil Appeals filed by Novartis AG with costs and held as follows:

The subject product, β-crystalline-Imatinib Mesylate (β-IM), failed both the test of invention as laid down in Sections 2(1)(j) and 2(1)(ja) of the Patents Act, 1970 and the test of enhanced efficacy or patentability under Section 3(d) read with its Explanation. Imatinib Mesylate was found to be a known substance disclosed in the Zimmermann Patent No. 5,521,184. The development of Imatinib Mesylate from Imatinib did not constitute a new invention. β-IM, being a polymorph (a specific crystalline form) of Imatinib Mesylate, was a "new form of a known substance" for the purposes of Section 3(d). Novartis had not demonstrated, through any empirical, clinical, or research data, that β-IM had any enhanced therapeutic efficacy compared to Imatinib Mesylate, the known substance. The improved physical properties of β-IM — such as better flow, thermodynamic stability, lower hygroscopicity, and 30% increased bioavailability — were not sufficient by themselves to constitute "enhanced efficacy" for the purposes of Section 3(d), since efficacy in the context of a medicine means therapeutic efficacy, which must be judged strictly and narrowly. The patent application for β-IM was therefore rightly rejected. The Court upheld R. 55 of Patent Rules, 2003 and held that no violation of Article 21 of the Constitution of India was made out. The appeals filed by Natco Pharma Limited and Cancer Patients Aid Association were allowed to the extent of affirming the rejection of Novartis's patent claim.

 

Point of Law Settled in the Case

This judgment settled several important points of law with lasting significance for Indian patent jurisprudence.

The Supreme Court authoritatively held that "invention" and "patentability" under the Patents Act, 1970 are two distinct and separate concepts. A product may qualify as an "invention" in a general sense and yet may not be patentable if it falls within one of the exclusions in Section 3 of the Act. Section 3(d) is not an ex majore cautela clause but a substantive provision that independently and mandatorily applies to all pharmaceutical and chemical substances of the nature described therein.

The Court settled that in the context of a new form of a known pharmaceutical or chemical substance, the applicant must cumulatively satisfy two tests: first, the invention test under Sections 2(1)(j) and 2(1)(ja), and second, the enhanced therapeutic efficacy test under Section 3(d) read with its Explanation. Both tests must be independently satisfied; clearing one does not exempt the applicant from the other.

The Court definitively interpreted "efficacy" in Section 3(d) as meaning "therapeutic efficacy" in the case of medicines and pharmaceuticals — that is, the ability of the medicine to produce the desired therapeutic effect in treating the disease for which it is prescribed. Physico-chemical properties such as improved flow, better stability, reduced hygroscopicity, or even increased bioavailability, by themselves, do not amount to "enhanced efficacy" unless they are specifically connected to and proven to result in better therapeutic outcomes, which must be established through research or empirical data.

The Court also settled the principle that patent coverage cannot exceed patent disclosure, and that a patent application that draws its very claims and averments from a prior patent (in this case the Zimmermann Patent) while simultaneously claiming to be independent of that prior patent will be critically scrutinized. A party is bound by the positions it has taken and benefited from in foreign proceedings involving the same subject matter.

The ruling firmly placed Section 3(d) as India's principal legislative safeguard against "evergreening" in the pharmaceutical industry — the practice of repeatedly patenting minor modifications of a known drug to extend patent-based monopolies and delay the availability of affordable generic medicines. This was characterized not merely as a matter of patent law but as a matter of public health policy.

 

Case Details

Title: Novartis AG Vs. Union of India and Others (with Natco Pharma Limited v. Union of India and Others, and Cancer Patients Aid Association v. Union of India and Others)

Date of Order: April 1, 2013

Case Numbers: Civil Appeals Nos. 2706-716 of 2013 (Novartis AG); Civil Appeal No. 2728 of 2013 (Natco Pharma Limited); Civil Appeals Nos. 2717-27 of 2013 (Cancer Patients Aid Association) — arising out of SLPs (C) Nos. 20539-49 of 2009, SLP (C) No. 32706 of 2009, and SLPs (C) Nos. 12984-94 of 2013

Neutral Citation / Published Citation: (2013) 6 SCC 1

Court: The Supreme Court of India

Bench: Hon'ble Mr. Justice Aftab Alam and Hon'ble Mrs. Justice Ranjana P. Desai, JJ.

 

Disclaimer: Readers are advised not to treat this as substitute for legal advice as it may contain errors in perception, interpretation, and presentation.

Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi

 

Suggested SEO Titles

1.    Novartis AG v. Union of India 2013: The Supreme Court Judgment That Changed Pharmaceutical Patent Law in India

2.    Section 3(d) Patents Act Explained: How India Defeated Novartis in the Gleevec Patent Case

3.    Evergreening of Pharmaceutical Patents in India: Lessons from Novartis v. Union of India (2013) 6 SCC 1

4.    Therapeutic Efficacy Test Under Section 3(d) of the Indian Patents Act: The Novartis Gleevec Ruling

5.    Beta-Crystalline Imatinib Mesylate Patent Refused: Supreme Court of India on New Forms of Known Substances

6.    TRIPS Compliance and Indian Patent Law: Analysis of the Novartis Glivec Case

7.    Anti-Evergreening Provision in Indian Patent Law: A Detailed Analysis of (2013) 6 SCC 1

 

SEO Tags

Novartis AG v Union of India, Section 3d Patents Act 1970, Gleevec patent India, Glivec patent case, Imatinib Mesylate patent, beta crystalline Imatinib Mesylate, pharmaceutical patent India, evergreening of patents, therapeutic efficacy test, Indian patent law, Patents Amendment Act 2005, TRIPS and Indian patent law, Supreme Court patent judgment 2013, patent and public health India, Aftab Alam judgment, Ranjana Desai Supreme Court, Zimmermann Patent, Natco Pharma, Cancer Patients Aid Association, new form of known substance, Section 2(1)(j) Patents Act, Section 2(1)(ja) Patents Act, inventive step India, patent eligibility pharmaceutical, product patent India, IPAB judgment patent, patent mailbox India, CML cancer drug patent, affordable medicines India, generic medicines patent, IP law India, intellectual property landmark judgment, patent evergreening prevention, bioavailability patent India, polymorph patent India, AdvocateAjayAmitabhSuman, IPAdjutor

 

Headnote

Novartis AG v. Union of India, (2013) 6 SCC 1 — Supreme Court of India — Bench: Aftab Alam and Ranjana P. Desai, JJ. — Decided on April 1, 2013

Held: Under the Patents Act, 1970 as amended by the Patents (Amendment) Act, 2005, "invention" and "patentability" are distinct concepts, and a substance must satisfy both the general invention test under Sections 2(1)(j) and 2(1)(ja) and the enhanced efficacy test under Section 3(d) in order to qualify for a patent in India. Section 3(d) is a substantive anti-evergreening provision and not a mere precautionary clause. In the case of pharmaceutical and chemical substances, "efficacy" within Section 3(d) means "therapeutic efficacy" — the ability of the medicine to produce the desired therapeutic result in treating the disease — and not merely improved physico-chemical properties. A new crystalline polymorph (beta-crystalline Imatinib Mesylate, β-IM) of a known pharmaceutical substance (Imatinib Mesylate) that does not demonstrate enhanced therapeutic efficacy over the known substance through research/empirical data is not patentable under Indian law. Imatinib Mesylate, being a known substance disclosed in Zimmermann Patent No. 5,521,184 (US), the claim for β-IM also failed the invention test. The drug Gleevec/Glivec (β-IM) marketed and sold as Imatinib Mesylate with no reference to the beta-crystalline form on its packaging indicated a deceptive patent claim. Appeals by Novartis dismissed with costs. Section 3(d) held to be TRIPS-compatible. Patent coverage cannot exceed patent disclosure. Indian Patent Law should not develop in a manner where patents are traded as commodities for litigation rather than for genuine invention and production.

 

SC-National Bell Co. and Gupta Industrial Corporation Vs. Metal Goods Mfg. Co. (P) Ltd

National Bell Co. & Anr. v. Metal Goods Manufacturing Co. (P) Ltd. & Anr.: Supreme Court Clarifies Distinctiveness, Validity of Registered Trade Marks and Scope of Rectification Proceedings

Introduction

Trade mark law seeks to strike a delicate balance between protecting commercial goodwill and preventing monopolization of common expressions or symbols. One recurring question in trade mark jurisprudence is whether a simple numeral can function as a valid trade mark and, if registered, under what circumstances its registration can later be challenged.

The Supreme Court's decision in National Bell Co. & Anr. v. Metal Goods Manufacturing Co. (P) Ltd. & Anr. is a landmark ruling that addresses these issues. The judgment examines the concepts of distinctiveness, conclusiveness of registration, rectification of the trade mark register, and the circumstances in which a registered trade mark may be cancelled. The Court also clarified the meaning of important provisions of the Trade and Merchandise Marks Act, 1958, particularly Sections 9, 11, 32 and 56.

The ruling remains significant for trade mark proprietors, businesses, intellectual property practitioners, and courts because it establishes that once a trade mark has remained registered for more than seven years, its validity attains a high degree of protection and can be challenged only on limited statutory grounds. The decision also demonstrates how even a numeral may acquire trade mark significance through commercial use and public recognition.

Factual and Procedural Background

The dispute concerned cycle bells sold under the marks "50" and "Fifty".

For several years prior to 1952, cycle bells manufactured by foreign concerns, particularly Lucas and certain other manufacturers, were available in India bearing numerals such as "30", "50", and "61". These numerals were used in relation to different varieties of bells. However, imports of foreign bells were prohibited after 1952. Although some imported bells continued to be sold until about 1958, such sales were largely from old stocks remaining in the market.

Metal Goods Manufacturing Co. (P) Ltd., the respondent company, obtained registration of two trade marks on 20 November 1953 in respect of cycle bells. One registration covered the numeral "50" (Trade Mark No. 161543) and the other covered the word "Fifty" (Trade Mark No. 161544).

The appellants, National Bell Co. Ltd. and Gupta Industrial Corporation, were also engaged in manufacturing and trading cycle bells. They marketed bells bearing numerals including "50". Gupta Industrial Corporation claimed use of bells bearing "50" since 1947, while National Bell Co. claimed use from 1957.

In 1959, the respondent instituted infringement suits against the appellants before the District Court at Lucknow alleging infringement of its registered trade marks. During the pendency of those suits, the appellants sought rectification of the trade mark register and cancellation of the respondent's registrations under Section 56 of the Trade and Merchandise Marks Act, 1958.

The appellants contended that the marks "50" and "Fifty" were common to the trade, lacked distinctiveness, were used by numerous manufacturers, had been copied from foreign manufacturers, and had ceased to distinguish the respondent's goods.

A learned Single Judge of the Punjab High Court accepted the challenge in part. While refusing to cancel the registration of the word mark "Fifty", the Single Judge ordered cancellation of the registration of the numeral "50" on the ground that it was not distinctive and had become common in the trade.

Appeals were preferred before a Division Bench of the High Court. The Division Bench reversed the cancellation order relating to the numeral "50" and upheld the validity of both registrations. Aggrieved by that decision, the appellants approached the Supreme Court.

Dispute Before the Court

The Supreme Court was required to determine whether the registered trade marks "50" and "Fifty" were liable to be removed from the register despite having remained registered for more than seven years.

The appellants argued that the marks lacked distinctiveness at the time of registration and therefore should never have been registered. According to them, numerals were generally incapable of functioning as distinctive trade marks. They also contended that use of the marks was likely to cause confusion because similar numerals had been used by foreign manufacturers and other traders. It was further argued that the respondent had merely imitated marks previously used by foreign manufacturers and therefore the marks were not entitled to protection. Finally, it was contended that by the time rectification proceedings commenced, the marks had ceased to be distinctive and had become common in the market.

The respondent, on the other hand, argued that the registrations had stood for more than seven years and therefore enjoyed statutory conclusiveness under Section 32 of the Act. It maintained that the marks had acquired distinctiveness through extensive use and that there was no evidence of fraud, deception, confusion, abandonment, or loss of distinctiveness sufficient to justify cancellation.

Reasoning and Analysis of the Court

The Supreme Court undertook an extensive examination of the scheme of the Trade and Merchandise Marks Act, 1958.

The Court first analysed Section 9, which deals with registrability and distinctiveness. Section 9(3) defines a distinctive mark as one adapted to distinguish the goods of a particular trader from those of others. The Court observed that distinctiveness may arise either inherently or through use and commercial recognition.

The Court then examined Sections 31 and 32. Section 31 makes registration prima facie evidence of validity. Section 32 goes further and provides that after seven years from registration, the validity of a trade mark registered in Part A of the Register becomes conclusive except in three limited situations: where registration was obtained by fraud, where the mark was registered in contravention of Section 11 or offends Section 11 at the commencement of proceedings, or where the mark is not distinctive at the commencement of proceedings.

A significant aspect of the judgment is the Court's interpretation of Section 56 relating to rectification. The Court held that an "aggrieved person" is not confined to a narrow category. The expression includes a person who has previously used the mark and also a person against whom infringement proceedings have been instituted. Thus, the appellants were entitled to maintain rectification proceedings.

However, the Court emphasized that because more than seven years had elapsed since registration, the appellants could not reopen the question whether the marks lacked distinctiveness at the time of original registration. Section 32 barred such a challenge unless one of the statutory exceptions was established.

The Court next examined the argument that numerals are inherently incapable of functioning as trade marks. Rejecting this broad proposition, the Court held that there is no inflexible rule that a numeral can never be distinctive. A numeral may become distinctive and capable of registration depending on the circumstances and the evidence of use.

While considering this issue, the Court referred to the observations in Kerly on Trade Marks and the English decision in Reuter v. Muhlens [1954 Ch. 50], where the numeral "4711" had been treated as a valid trade mark. The Court concluded that numerals are capable of registration and protection when they acquire distinctiveness.

The Court then addressed Section 11(a), which prohibits registration of marks likely to deceive or cause confusion. The evidence showed that imported bells bearing numerals had substantially disappeared from the market after the import restrictions of 1952. Whatever sales continued thereafter were from residual stock and were minimal.

The Court found that consumers ordinarily identified foreign bells by the manufacturer's name, such as Lucas, rather than by the numeral appearing on them. Similarly, there was insufficient evidence regarding the extent of manufacture and sale of bells bearing "50" by the appellants. In contrast, the respondent had produced substantial evidence showing steadily increasing sales of its bells from 1949 onwards. Accordingly, the Court concluded that there was no sufficient evidence of confusion or deception to attract Section 11(a).

The Court also rejected the allegation that the respondent had pirated or copied the marks of foreign manufacturers. It noted that there was no evidence that Lucas or any foreign manufacturer had obtained registration of either "50" or "Fifty" as trade marks. Those numerals were merely used as indicators of type or model. The respondent was the first trader to convert them into registered trade marks in India.

While interpreting Section 11(e), which prohibits registration of marks "otherwise disentitled to protection in a court", the Court delivered an important clarification. Relying upon the English decision in Imperial Tobacco Co. Ltd. v. De Pasquali & Co., 35 RPC 185, the Court held that Section 11 is concerned with positive grounds of prohibition and not with mere absence of registrability requirements under Section 9. Therefore, a mark is not "disentitled to protection" merely because it might not originally have satisfied the distinctiveness requirement.

The Court further examined whether the marks had ceased to be distinctive under Section 32(c). It explained that trade mark rights may be lost if a mark becomes publici juris, is abandoned, or ceases to indicate a connection between the goods and their proprietor.

In this context, the Court discussed the principles emerging from Re Farina (1879) 27 WR 456 and Rowland v. Mitchell (1897) 14 RPC 37. These authorities recognise that abandonment cannot lightly be inferred and that occasional failures to take action against infringement do not necessarily destroy trade mark rights.

Applying those principles, the Court found that the respondent had consistently enforced its rights. It had initiated infringement proceedings against several traders, opposed conflicting registrations, and actively protected its marks whenever substantial infringement came to its notice. There was no evidence of widespread and substantial third-party use sufficient to render the marks common to the trade.

The Court therefore held that the marks remained distinctive both at the time of the infringement suits in 1959 and at the commencement of rectification proceedings in 1961.

The Court also observed that rectification under Section 56 is a discretionary remedy. Since the Single Judge had not properly appreciated the interplay between Sections 11 and 32, the Division Bench was justified in reversing the rectification order.

Final Decision of the Court

The Supreme Court dismissed both appeals.

The Court upheld the judgment of the Division Bench of the Punjab High Court and confirmed the validity of the respondent's registered trade marks "50" and "Fifty". The order of the Single Judge cancelling the registration of the numeral "50" was effectively set aside.

The rectification applications seeking cancellation of the trade marks failed. The Court held that none of the statutory grounds contained in Section 32 had been established. Consequently, the registrations remained on the trade mark register and the respondent retained the benefit of its statutory rights as proprietor of the registered marks.

Costs were awarded against the appellants.

Point of Law Settled

The judgment establishes and clarifies several important principles of Indian trade mark law.

First, after seven years from registration, the validity of a registered trade mark becomes conclusive under Section 32 except on the limited grounds specifically mentioned in that provision.

Secondly, a challenge based on lack of distinctiveness at the time of original registration cannot ordinarily be entertained after the expiry of seven years.

Thirdly, a numeral is not inherently incapable of functioning as a trade mark. If a numeral acquires distinctiveness through use and public recognition, it may be validly registered and protected.

Fourthly, the expression "disentitled to protection in a court" under Section 11(e) refers to positive grounds of legal objection and does not include every case where a mark may have lacked registrability under Section 9.

Finally, abandonment or loss of distinctiveness cannot be inferred merely because some infringements went unchallenged. To establish that a mark has become common to the trade, substantial and widespread use by others must be proved.

The decision continues to serve as a leading authority on trade mark distinctiveness, conclusiveness of registration, rectification proceedings, and protection of numerical trade marks in India.


Case Details:

Title of the Case: National Bell Co. & Anr. v. Metal Goods Manufacturing Co. (P) Ltd. & Anr.

Date of Judgment/Order: 18 March 1970

Case Number: Civil Appeal Nos. 1952 and 1953 of 1966

Neutral Citation: Not Available

Equivalent Citations: AIR 1971 SC 898; (1970) 1 SCC 665; (1971) 1 SCR 70

Name of Court: Supreme Court of India

Name of Hon'ble Judge: Justice J. M. Shelat and Justice C. A. Vaidialingam


Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi

Disclaimer: Images used herein do not reflect actual images used in Judgement and that the same are for illustrative purpose only. Readers are advised not to treat this as substitute for legal advice as it may contain errors in perception, interpretation, and presentation.


Suggested SEO Titles:

  1. Supreme Court on Numerical Trade Marks: Analysis of National Bell Co. v. Metal Goods Manufacturing Co.

  2. Can a Number Be a Trade Mark? Understanding the National Bell Judgment

  3. Distinctiveness and Rectification under Trade Mark Law: Supreme Court's Landmark Ruling

  4. National Bell Case Explained: Seven-Year Validity Rule in Trade Mark Registration

  5. Supreme Court Clarifies Section 32 of the Trade and Merchandise Marks Act

  6. Trade Mark Rectification and Distinctiveness: Lessons from National Bell v. Metal Goods

  7. Legal Protection of Numerical Trade Marks in India: National Bell Case Analysis

  8. When Can a Registered Trade Mark Be Cancelled? Supreme Court Explains

  9. Section 11 and Section 32 of the Trade Marks Law Interpreted by the Supreme Court

  10. National Bell Judgment: Conclusive Validity of Trade Mark Registration After Seven Years

  11. Abandonment and Common Use in Trade Mark Law: Supreme Court Perspective

  12. Trade Mark Distinctiveness and Publici Juris Doctrine Explained Through National Bell


Suggested SEO Tags:

Trademark Law India, Trade Mark Rectification, Numerical Trademark, Number Trademark Registration, Distinctiveness of Trademark, Section 32 Trade and Merchandise Marks Act, Section 56 Trademark Rectification, Trademark Cancellation, Trademark Infringement India, Trademark Validity, Conclusive Registration Rule, Trademark Litigation, Intellectual Property Law India, Trademark Disputes, Common to Trade Doctrine, Publici Juris Trademark, Abandonment of Trademark Rights, Section 11 Trademark Act, Distinctive Marks, Registered Trademark Protection, Cycle Bell Trademark Case, Supreme Court Trademark Judgment, Trademark Jurisprudence India, Trademark Enforcement, Trademark Proprietor Rights, Passing Off and Trademark Law, AdvocateAjayAmitabhSuman, IPAdjutor


Headnote of the Judgment:

National Bell Co. & Anr. v. Metal Goods Manufacturing Co. (P) Ltd. & Anr., Supreme Court of India, Civil Appeal Nos. 1952 and 1953 of 1966, decided on 18 March 1970. The appeals arose from rectification proceedings seeking cancellation of the registered trade marks "50" and "Fifty" used for cycle bells. The Supreme Court examined Sections 9, 11, 32 and 56 of the Trade and Merchandise Marks Act, 1958, and held that after seven years of registration, validity of a trade mark becomes conclusive except on limited statutory grounds. The Court ruled that numerals can acquire distinctiveness and function as valid trade marks. Finding no fraud, deception, loss of distinctiveness, abandonment, or substantial common use, the Court dismissed the appeals and upheld the respondent's registrations.


Info-graphic Thumbnail Prompt:

Create a premium 3D hyper-realistic 8K legal-news infographic thumbnail, 14:9 aspect ratio. Central focus on a glowing metallic numeral “50” transforming into a protected trademark symbol, representing trademark distinctiveness and legal protection. Display luxury cycle bell elements, trademark registry dashboard, legal shield, digital registration certificate, courtroom-inspired architecture, glowing legal analytics charts, IP law icons, rectification register visuals, exclusivity and brand identity concepts. Premium red, gold, black and metallic silver palette with glowing amber highlights. Ultra-sharp details, cinematic lighting, realistic reflections, depth-of-field effects, modern intellectual property law aesthetics, high-end legal journalism style. Minimal text only: “TRADEMARK VALIDITY” and “NUMERAL MARKS”. Include visual themes of distinctiveness, trademark registration, legal protection after seven years, and anti-counterfeiting enforcement. Use realistic 3D charts, legal dashboards, tables, and visual storytelling rather than large blocks of text. Avoid clutter. Do not use name of any court, lawyer, tricolor, Ashoka Emblem and any other government insignia. Use generic images. Use attached image as Image of lawyer in lawyers dress at left bottom corner which should cover 20 % of entire image area.

SC-Nandhini Deluxe Vs. Karnataka Co-Operative Milk Producers Federation Ltd

Nandhini Deluxe v. Karnataka Co-Operative Milk Producers Federation Ltd.: Supreme Court Clarifies Limits of Trademark Monopoly Across Different Goods

Introduction

The decision of the Supreme Court in Nandhini Deluxe v. Karnataka Co-Operative Milk Producers Federation Ltd. is one of the most important trademark judgments in India dealing with the scope of protection available to a registered trademark when similar marks are used for different goods and services. The dispute revolved around the use of the marks “NANDINI” and “NANDHINI”, raising questions about deceptive similarity, likelihood of confusion, well-known trademarks, concurrent use, and the extent to which a trademark proprietor can claim exclusivity over an entire class of goods.

The judgment is significant not only for trademark owners and businesses but also for legal practitioners and intellectual property professionals because it clarifies that trademark protection cannot be stretched beyond reasonable limits merely because a mark has acquired reputation in relation to specific goods. The ruling reinforces the principle that courts must examine the overall commercial context, nature of goods, manner of use, and the likelihood of actual confusion before denying registration to a later user.

Factual and Procedural Background

The dispute arose between Nandhini Deluxe, a restaurant business operating under the mark “NANDHINI”, and Karnataka Co-Operative Milk Producers Federation Ltd. (KMF), a well-known cooperative federation engaged in the manufacture and sale of milk and milk products under the mark “NANDINI”.

KMF adopted and began using the trademark “NANDINI” in 1985 for milk and dairy products. Over time, the mark became widely known in Karnataka and several registrations were obtained in different classes relating to dairy products and allied goods. The federation also invested heavily in promotion and marketing of its products.

Nandhini Deluxe adopted the mark “NANDHINI” in 1989 for its restaurant business. Subsequently, it applied for registration of the mark in respect of various food-related products falling in Classes 29 and 30 of the Trade Marks Act. KMF opposed these applications on the ground that “NANDHINI” was deceptively similar to its registered trademark “NANDINI” and was likely to cause confusion among consumers.

The Deputy Registrar of Trade Marks examined the matter and concluded that the applicant had honestly and concurrently used the mark since 1989. The Registrar observed that the parties were dealing in different goods and that there was insufficient evidence of actual confusion. Registration was therefore permitted, subject to deletion of “milk and milk products” from the specification of goods claimed by Nandhini Deluxe.

KMF challenged this decision before the Intellectual Property Appellate Board (IPAB). In one round of litigation, the IPAB relied upon the Supreme Court decision in Vishnudas Trading v. Vazir Sultan Tobacco Co. Ltd., (1997) 4 SCC 201, and held that a proprietor dealing only in specific goods could not claim monopoly over all goods falling within a broad class.

However, in another set of appeals decided on 4 October 2011, the IPAB took a different view. It held that “NANDINI” had acquired distinctiveness and reputation and that registration of “NANDHINI” could create confusion among consumers. Consequently, it allowed KMF’s appeals and set aside the Registrar’s decision.

Nandhini Deluxe challenged the IPAB’s order before the Karnataka High Court. The High Court upheld the IPAB’s reasoning. Aggrieved by this decision, Nandhini Deluxe approached the Supreme Court through Civil Appeal Nos. 2937-2942 and 2943-2944 of 2018.

Dispute Before the Court

The principal issue before the Supreme Court was whether the trademark “NANDHINI” sought to be registered by the appellant was deceptively similar to the respondent’s registered trademark “NANDINI” and whether such registration was prohibited under the Trade Marks Act, 1999.

The Court was also required to determine whether the respondent’s reputation in relation to milk and milk products entitled it to prevent registration of a similar mark in relation to other food products and restaurant-related goods. Another important question was whether the respondent could claim exclusive rights over all goods falling within the same trademark classes despite using the mark primarily for dairy products.

Nandhini Deluxe argued that the goods and services of the parties were fundamentally different, that it had honestly used the mark since 1989, and that the word “NANDHINI” was a common religious and mythological expression not capable of exclusive appropriation. KMF, on the other hand, contended that “NANDINI” had become a well-known trademark and that registration of “NANDHINI” would mislead consumers into believing that the appellant’s goods originated from or were associated with KMF.

Reasoning and Analysis of the Court

The Supreme Court undertook a detailed examination of Sections 11, 12 and 18 of the Trade Marks Act, 1999 and the principles governing deceptive similarity and trademark protection.

The Court first identified several undisputed facts. It noted that KMF was the prior user, having adopted “NANDINI” in 1985, whereas Nandhini Deluxe adopted “NANDHINI” in 1989. However, the Court also observed that Nandhini Deluxe had continuously used the mark for many years before seeking registration. The Court further emphasized that the goods of the parties were materially different. While KMF dealt in milk and dairy products, Nandhini Deluxe operated restaurants and sought registration for various food items used in connection with its restaurant business. Moreover, Nandhini Deluxe had already abandoned its claim relating to milk and milk products.

The Court carefully compared the rival marks. It observed that although there was phonetic similarity between “NANDINI” and “NANDHINI”, the marks had to be examined in their entirety. The appellant’s mark consisted of “NANDHINI DELUXE”, accompanied by a lamp device and the slogan “the real spice of life”, whereas the respondent used “NANDINI” with a cow logo. The visual appearance, trade dress, and overall commercial impression were significantly different. The Court concluded that the marks were not deceptively similar when viewed as a whole.

The Court relied upon the principles laid down in Polaroid Corporation v. Polarad Electronics Corporation, 287 F.2d 492 (2d Cir. 1961), which emphasize factors such as strength of the mark, similarity of marks, proximity of goods, likelihood of expansion, evidence of actual confusion, good faith adoption, and consumer sophistication. Applying these factors, the Court found no substantial likelihood of confusion.

The Court also referred to Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., (2001) 5 SCC 73, a leading Indian authority on deceptive similarity, as well as Shree Nath Heritage Liquor Pvt. Ltd. v. Allied Blender and Distillers Pvt. Ltd., (2015) 221 DLT 359, and the American decision in Polaroid. These authorities were cited in the context of determining likelihood of confusion and assessing competing trademarks.

A major aspect of the judgment was the Court’s reliance on Vishnudas Trading v. Vazir Sultan Tobacco Co. Ltd., (1997) 4 SCC 201. The Supreme Court reaffirmed the principle that a trademark proprietor cannot claim monopoly over an entire class of goods merely because registration exists in that class. Where a proprietor uses the mark only for specific goods and has no bona fide intention to use it for all goods in the class, exclusive rights must be confined accordingly.

The Court also examined the argument that “NANDINI” was a well-known trademark under Section 11(2) of the Trade Marks Act. Referring to Nestle India Ltd. v. Mood Hospitality Pvt. Ltd., (2010) 42 PTC 514 (Del) (DB), the Court noted that additional requirements must be satisfied before protection available to a well-known mark can be extended to dissimilar goods. The Court found that these requirements had not been established. There was no evidence that the appellant had adopted the mark to take unfair advantage of the respondent’s reputation or that use of “NANDHINI” for the appellant’s goods would damage the distinctiveness of the respondent’s mark.

The Court further observed that the appellant’s adoption of the mark dated back to 1989 and appeared to be a case of honest concurrent use rather than an attempt to exploit the respondent’s goodwill. The absence of evidence showing consumer confusion weighed heavily against the respondent.

Another noteworthy aspect of the judgment was the Court’s observation that the IPAB had ignored its own earlier decision rendered between the same parties on a substantially similar issue. The Court noted that principles of issue estoppel could arguably apply, referring to Bhanu Kumar Jain v. Archana Kumar, (2005) 1 SCC 787 and Hope Plantations Ltd. v. Taluk Land Board, (1999) 5 SCC 590. Although the Court did not decide the matter solely on that ground, it acknowledged the force of the appellant’s contention.

Final Decision of the Court

The Supreme Court held that the orders of the IPAB and the Karnataka High Court were legally unsustainable. It concluded that the marks, when considered in their entirety, were not deceptively similar and that registration of “NANDHINI” in respect of the appellant’s goods would not cause confusion or deception among consumers.

Accordingly, the Court allowed the appeals, set aside the orders of the IPAB and the High Court, and restored the order of the Deputy Registrar granting registration in favour of Nandhini Deluxe. However, the registration remained subject to the condition that the appellant would not obtain registration in respect of milk and milk products, which had already been excluded from its claim.

Point of Law Settled

The judgment establishes that trademark protection cannot automatically extend to every product falling within a broad class of goods merely because the proprietor owns a registered mark in that class. Courts must examine the actual nature of the goods, the manner of trade, the visual and phonetic features of the competing marks, and the realistic likelihood of consumer confusion.

The decision further clarifies that even where a trademark enjoys considerable reputation, protection under Section 11(2) of the Trade Marks Act cannot be extended to dissimilar goods unless the statutory requirements relating to reputation, unfair advantage, and detriment are clearly established. The ruling reinforces the principle that honest concurrent use and differences in business activities remain important considerations in trademark registration disputes.


Case Details

Title of the Case: Nandhini Deluxe v. Karnataka Co-Operative Milk Producers Federation Ltd.

Date of Judgment/Order: 26 July 2018

Case Number: Civil Appeal Nos. 2937-2942 and 2943-2944 of 2018

Neutral Citation: MANU/SC/0779/2018; (2018) 9 SCALE 202

Name of Court:

Name of Hon'ble Judge: and


Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi

Disclaimer: Images used herein do not reflect actual images used in Judgment and the same are for illustrative purposes only. Readers are advised not to treat this article as a substitute for legal advice as it may contain errors in perception, interpretation, and presentation.


Suggested SEO Titles

  1. Supreme Court on Trademark Monopoly: Nandhini Deluxe v. Karnataka Co-Operative Milk Producers Federation Explained
  2. Nandhini vs Nandini Trademark Dispute: Landmark Supreme Court Judgment Analysis
  3. Can a Trademark Owner Claim Rights Over an Entire Class of Goods? Supreme Court Answers
  4. Nandhini Deluxe Case: Supreme Court Clarifies Scope of Well-Known Trademark Protection
  5. Trademark Infringement and Deceptive Similarity: Lessons from Nandhini Deluxe Judgment
  6. Supreme Court Restores Nandhini Deluxe Trademark Registration in Landmark IP Case
  7. Nandhini Deluxe v. KMF: Detailed Analysis of Section 11 of the Trade Marks Act
  8. Well-Known Trademarks and Honest Concurrent Use: Supreme Court’s Nandhini Deluxe Ruling
  9. Trademark Registration for Different Goods: Supreme Court Clarifies the Law
  10. Nandhini Deluxe Judgment: Key Principles on Consumer Confusion and Trademark Rights

Suggested SEO Tags

Nandhini Deluxe case, Nandini trademark dispute, Karnataka Milk Federation trademark case, Supreme Court trademark judgment, Trade Marks Act 1999, Section 11 Trade Marks Act, well known trademark India, deceptive similarity trademark, trademark registration India, trademark opposition, IPAB decision, intellectual property law India, trademark litigation, honest concurrent use, trademark infringement law, likelihood of confusion, trademark classes, dairy products trademark, restaurant trademark dispute, Vishnudas Trading case, Cadila Health Care case, Nestle India trademark case, trademark monopoly, trademark jurisprudence India, Supreme Court IP law, trademark protection India, brand protection law, AdvocateAjayAmitabhSuman, IPAdjutor


Headnote of the Judgment

Nandhini Deluxe v. Karnataka Co-Operative Milk Producers Federation Ltd., Supreme Court of India, Civil Appeal Nos. 2937-2942 and 2943-2944 of 2018, decided on 26 July 2018. The appeals challenged the Karnataka High Court judgment affirming orders of the IPAB that had refused registration of the trademark “NANDHINI” in favour of the appellant. The Supreme Court held that although the respondent’s mark “NANDINI” enjoyed substantial reputation in relation to milk and dairy products, the appellant’s goods and business were materially different and there was no likelihood of confusion. The Court restored the Deputy Registrar’s order granting registration to the appellant, subject to exclusion of milk and milk products, and reaffirmed that trademark proprietors cannot claim monopoly over an entire class of goods without actual use.


Info-graphic Thumbnail Prompt

3D Hyper-Realistic 8K Legal News Thumbnail, 14:9 Aspect Ratio, premium intellectual property law theme, central focus on trademark battle between two competing brand identities represented through futuristic glowing wordmarks “NANDINI” vs “NANDHINI”, dramatic courtroom-inspired environment without court symbols, realistic 3D trademark registration certificates, glowing legal scales, premium legal dashboards, digital IP protection shields, confusion-analysis charts, brand comparison graphics, realistic product-category segregation visuals showing dairy products on one side and restaurant/food business on the other side, cinematic lighting, ultra-sharp reflections, metallic silver legal interface, premium red, black, gold and glowing amber highlights, luxury legal-news studio aesthetics, strong contrast, depth of field, volumetric lighting, modern intellectual property litigation theme, minimal text only: “TRADEMARK RIGHTS” and “SUPREME COURT RULING”, realistic data visualization panels, high-end magazine cover composition, uncluttered layout, professional legal journalism appearance, photorealistic rendering, award-winning visual storytelling, no court building, no national symbols, no Ashoka Emblem, no tricolor, no government insignia. Use attached image as Image of lawyer in lawyers dress at left bottom corner which should cover 20 % of entire image area.

Blog Archive

Featured Post

WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING

WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING IN ORDER TO PROVE THE TRADEMARK  REGISTRA...

My Blog List

IPR UPDATE BY ADVOCATE AJAY AMITABH SUMAN

IPR UPDATE BY ADVOCATE AJAY AMITABH SUMAN

Search This Blog